ADAPTIMMUNE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.89 USD | +1.97% |
|
-11.88% | +12.23% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Adaptimmune's Call to Di...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Companyâs most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
0.89
USD
Average target price
2.519
USD
Spread / Average Target
+183.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.23% | 227M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- ADAP Stock
- News Adaptimmune Therapeutics plc
- Transcript : Adaptimmune Therapeutics plc - Special Call
